Bioavailability, FDA Approval and Immune Response

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioavailability

FDA Approval

Immune Response

Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence?

Delveinsight

SEPTEMBER 8, 2021

Hydroxychloroquine and BENLYSTA are the FDA-approved therapies for SLE treatment. With the approval of these therapies, the outlook for SLE patients improved from a 4-year survival rate of ~50% in 1950 to a 15-year survival rate of ~85% by 2013. Saphnelo is also being evaluated for SLE in the European Union and Japan.

Marketing

Marketing Sales FDA Approval Antibody

Novartis’ Fabhalta (Iptacopan) Earns Third FDA Nod, This Time for C3G

XTalks

MARCH 24, 2025

Fabhalta works by inhibiting factor B, a key enzyme in the alternative complement pathway, thus calming the damaging immune response. The APPEAR-C3G Phase III study enrolled 74 adults with biopsy-confirmed C3G. In this study, Fabhalta produced a 35% reduction in proteinuria after six months compared to placebo.

Bioavailability

Bioavailability Immune Response Protein Bacteria

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Clinical Research Informer

Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence?

Novartis’ Fabhalta (Iptacopan) Earns Third FDA Nod, This Time for C3G

Webinars

Stay Connected